DAVID GRANOVSKY

Posts Tagged ‘lymph’

SYSTEM CONNECTING BRAIN TO IMMUNE SYSTEM FOUND – AUTISM RECONSIDERED?

In ALL ARTICLES on September 16, 2015 at 11:47 am
“In contradiction to decades of medical education, a direct connection has been reported between the brain and the immune system….It seems astonishing that, after centuries of dissection, a system of lymphatic vessels could have survived undetected.”

EVERY time I have a conversation with someone who is 100% sure, I laugh inside and remember that everything we know for sure will be disproved within our lifetimes.
 
Medical science was 100% sure:
the heart doesn’t regenerate…wrong
the brain and central nervous system doesn’t regenerate…wrong
all of the ligaments have been found…wrong
butter is healthier, margarine is healthier, butter, margarine…wrong
stem cells don’t work…wrong
cholesterol is bad…wrong
and on and on and on and now…
 
This changes everything.

“It changes entirely the way we perceive the neuro-immune interaction,” says Kipnis. “We always perceived it before as something esoteric that can’t be studied. But now we can ask mechanistic questions.”

MS is known to be an example of the immune system attacking the brain, although the reasons are poorly understood. The opportunity to study lymphatic vessels that link the brain to the immune system could transform our understanding of how these attacks occur, and what could stop them. The causes of Alzheimer’s disease are even more controversial, but may also have immune system origins, and the authors suggest protein accumulation is a result of the vessels failing to do their job.

Indeed, Kipnis claims, “We believe that for every neurological disease that has an immune component to it, these vessels may play a major role.”

This changes everything.

Every single study dealing with brain and immune and GI systems must be revisited and re-evaluated.

For example, it begs the question…With so many people saying Autism is a neurological malfunction and so many people saying Autism is immune system caused and so many saying it is nutritional and heavy metal toxin caused…if these systems are all interconnected, perhaps they are all right.  Is it time to reconsider the cause (causes!) of Autism?

http://www.iflscience.com/brain/vessels-found-connect-immune-system-and-brain

Allogeneic Stem Cell Transplantation Viable for Children and Adolescents with Relapsed Hodgkin’s Lymphoma

In SCIENCE & STEM CELLS on September 28, 2009 at 11:01 pm

Browse > Home / Hodgkin’s Lymphoma, News, Progressive Relapsed Hodgkin’s Lymphoma / Allogeneic Stem Cell Transplantation Viable for Children and Adolescents with Relapsed Hodgkin’s Lymphoma

Allogeneic Stem Cell Transplantation Viable for Children and Adolescents with Relapsed Hodgkin’s Lymphoma

September 24, 2009

Children and adolescents with relapsed Hodgkin’s lymphoma respond well to allogeneic stem cell transplantation, according to the results of a study published in Blood.[1]

Although children and adolescents with Hodgkin’s lymphoma have an excellent prognosis, some do relapse. These patients may benefit from stem cell transplantation, which involves the delivery of high doses of chemotherapy, followed by the infusion of stem cells, which serve to “rescue” bone marrow and hasten blood cell production and immune system recovery. Autologous stem cell transplants involve the patient’s own stem cells, whereas allogeneic stem cell transplants require the collection of donor stem cells.

Allogeneic stem cell transplantation has not been widely used in children and adolescents with Hodgkin’s lymphoma because of a high rate of nonrelapse mortality (NRM), which is mainly caused by acute and/or chronic graft-versus-host disease (GVHD); GVHD occurs when the patient’s body rejects the donor cells. Researchers from the European Group for Blood and Marrow Transplantation conducted a study that involved 91 children age 18 or younger with relapsed or refractory Hodgkin’s lymphoma who were treated with an allogeneic stem cell transplant between 1987 and 2005. Fifty-one patients received reduced intensity conditioning (RIC) (lower doses of chemotherapy), and 40 patients received myeloablative conditioning (MAC) (higher doses of chemotherapy). (Of the 40 patients who had failed a prior autologous transplant, 32 received RIC.) The results of the study indicated the following:

  • Non-relapse mortality at one year was 21%, with similar results for RIC or MAC.
  • The two-year relapse rate was 36%.
  • The five-year relapse rate was 44%.
  • There were more relapses in the RIC group than the MAC group.
  • Progression-free survival was 40%.
  • Overall survival was 54%.

The researchers concluded that allogeneic stem cell transplantation “is a viable treatment strategy for children and adolescents with relapsed Hodgkin’s lymphoma who failed most if not all other options available.” Reference: [1] Claviez A, Canals C, Dierickx D, et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin’s lymphoma: An analysis of the European Group for Blood and Marrow Transplantation. Blood. 2009; 114: 2060-2067.

via Allogeneic Stem Cell Transplantation Viable for Children and Adolescents with Relapsed Hodgkin’s Lymphoma | CancerConsultants.

Excellent SC Mobilization + Safety Profile for TG-0054

In BUSINESS OF STEM CELLS on September 28, 2009 at 9:21 pm

Excellent SC Mobilization + Safety Profile for TG-0054

TAIPEI, Taiwan, Sept. 28 /PRNewswire-Asia/ — TaiGen Biotechnology Co., Ltd. announced today that in a phase 1 study in healthy volunteers TG-0054, a chemokine receptor CXCR4 antagonist, was well tolerated and rapidly mobilized stem cells and endothelial progenitor cells from bone marrow into peripheral blood. The number of CD34+ stem cells in circulation after one dose of TG-0054 was equal or higher than reported cell numbers needed for stem cell transplantation in cancer patients. The observed AEs were all mild and transient. A phase 2 study in stem cell transplantation for multiple myeloma, non-Hodgkin lymphoma and Hodgkin disease patients is currently being initiated.

The trial was a randomized, double-blind, placebo-controlled, single intravenous dose study including 64 healthy volunteers in US, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of TG-0054 in 8 cohorts. The mobilized stem and progenitor cells peaked at 4-6 hours following one single intravenous dose.

“We are greatly encouraged by the phase 1 study results which indicates that TG-0054 has the potential to be used alone, not in combination with G- CSF, for allogenic or autologous stem cell transplantation in cancer patients. This should greatly reduce the hospital and other associated cost for such a procedure. Importantly, the activity and safety profile in the phase 1 study will support our future development of TG-0054 in chemosensitization and tissue ischemia, including myocardial infarction, stroke and severe intermittent claudication. Our preclinical animal disease models and the phase 1 study results lend strong support to clinical development for these clinical indications,” said Dr. Ming-Chu Hsu, Chairman & CEO of TaiGen.

via Excellent Stem Cell Mobilization and Safety Profile for TG-0054.

Pitt Researchers Grab $5M in Grants

In BUSINESS OF STEM CELLS on September 28, 2009 at 9:14 pm

Science Pitt Researchers Grab $5M in Grants for Stem Cell Research

SCIENCE CELLSShane McGlaun (Blog) – September 28, 2009 11:30 AM

Researchers working on growing tissues inside of lymph nodes from stem cells

Researchers at the University of Pittsburgh have received two grants that total over $5 million from the National Institutes of Health (NIH) to explore new methods for cultivating replacement cells from inside the body and organs. The grant will be used to study ways to coax stem cells to grow into specific types of tissue inside the lymph nodes of the body.

One of the grants was for $2.9 million and was awarded to Eric Lagasse, a professor of pathology in Pitt’s School of Medicine. Lagasse is also a researcher in the McGowan Institute for Regenerative Medicine. He will use the funds on research to use the many lymph nodes in the body as sites for growing replacement cells for other tissues. His research will use the lymph nodes as bioreactors to grow cells within the body.

via DailyTech – Pitt Researchers Grab $5M in Grants for Stem Cell Research.

%d bloggers like this: